CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
MD1003drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02967679
NCT02967679Phase 2Completed
CompareCT.gov

SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

MedDay Pharmaceuticals SA·interventional·Posted Nov 18, 2016·Updated Nov 2, 2020

In Brief

A Phase 2 clinical trial evaluating MD1003 for Chronic Inflammatory Demyelinating Polyneuropathy and 5 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A, Charcot-Marie-Tooth Disease, Type 1B, Anti-MAG Neuropathy
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 18, 2016
Enrollment StartDec 5, 2016
Primary CompletionMar 18, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.6 years ago

Interventions

MD1003drug